Niche focus Small-sized pharma consulting firm specializing in preformulation through manufacturing, with added IP and licensing due diligence capabilities—opportunity to position scalable, modular services for growing biopharma startups and mid-stage companies needing end-to-end CMC support.

End-to-end CMC Offer value through integrated CMC program viability assessments, formulation IP reviews, and potential commercial manufacture suitability, aligning with FinnBrit’s existing strengths to upsell broader development and late-stage manufacturing packages.

IP and deals Leverage expertise in intellectual property review and expert witness support to target pharmaceutical companies pursuing licensing, partnerships, or M&A, presenting FinnBrit as a strategic due diligence partner for deal-ready formulations.

Growth readiness Target early-stage to mid-size pharma players seeking specialized guidance to de-risk development timelines, reduce regulatory hurdles, and accelerate market entry, aligning services with their likely budget and need for external expertise.

Low footprint, high impact With a lean team and revenue in the lower mid-range, propose scalable advisory retainers, fractional CMC leadership, and modular consulting services that expand capacity without significant headcount increases, appealing to financially prudent clients.